The monoclonal antibody (mAb) field has come a long way since the first therapeutic mAb was commercialized in 1986. As of today, over 60 mAbs have been approved in the US and Europe and sales of mAbs are expected to cross $125 billion by 2020. Efficient recovery and purification of mAbs from cell culture medium is a critical part of the production process and can contribute significantly to the total manufacturing costs. In this ebook, experts from GE Healthcare share their advice on chromatography resins and purification.
>> Download the ebook
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
